Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Infinity Pharmaceuticals, Inc. INFI
$0.18
-$0 (-0.55%)
На 18:01, 12 мая 2023
+1 566.67%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
16435781.00000000
-
week52high
1.76
-
week52low
0.12
-
Revenue
2593000
-
P/E TTM
-377
-
Beta
1.34636600
-
EPS
-0.55000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 20:00
Описание компании
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Truist Securities | Buy | Buy | 31 мар 2022 г. |
| Piper Sandler | Overweight | Overweight | 30 мар 2022 г. |
| HC Wainwright & Co. | Buy | 18 окт 2021 г. | |
| JP Morgan | Overweight | Neutral | 02 авг 2021 г. |
| B. Riley Securities | Neutral | Buy | 16 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Peluso Stephane | D | 0 | 50000 | 02 авг 2022 г. |
| Peluso Stephane | A | 37052 | 14994 | 02 авг 2022 г. |
| Peluso Stephane | A | 52046 | 50000 | 02 авг 2022 г. |
| EVNIN ANTHONY B | A | 45000 | 45000 | 16 июн 2022 г. |
| EVNIN ANTHONY B | A | 215403 | 46378 | 16 июн 2022 г. |
| BEIER DAVID W | A | 45000 | 45000 | 16 июн 2022 г. |
| Agresta Samuel | A | 45000 | 45000 | 16 июн 2022 г. |
| GAYNOR RICHARD | A | 45000 | 45000 | 16 июн 2022 г. |
| SELBY NORMAN C | A | 10000 | 10000 | 16 июн 2022 г. |
| SELBY NORMAN C | A | 45000 | 45000 | 16 июн 2022 г. |
Новостная лента
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
28 мар 2023 г. в 19:04
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know
Zacks Investment Research
28 мар 2023 г. в 11:29
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
Benzinga
14 мар 2023 г. в 08:02
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
Zacks Investment Research
17 ноя 2022 г. в 11:17
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 11:24
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Edward Tenthoff - Piper Sandler Soumit Roy - Jones Research Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by.